药物发现
制药工业
药学
生物技术
计算生物学
桥接(联网)
透视图(图形)
制药工业
工程伦理学
数据科学
生物
计算机科学
药理学
生物信息学
工程类
人工智能
计算机网络
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2000-03-17
卷期号:287 (5460): 1960-1964
被引量:2630
标识
DOI:10.1126/science.287.5460.1960
摘要
Driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the progress of medicine during the past century than any other scientific factor. The advent of molecular biology and, in particular, of genomic sciences is having a deep impact on drug discovery. Recombinant proteins and monoclonal antibodies have greatly enriched our therapeutic armamentarium. Genome sciences, combined with bioinformatic tools, allow us to dissect the genetic basis of multifactorial diseases and to determine the most suitable points of attack for future medicines, thereby increasing the number of treatment options. The dramatic increase in the complexity of drug research is enforcing changes in the institutional basis of this interdisciplinary endeavor. The biotech industry is establishing itself as the discovery arm of the pharmaceutical industry. In bridging the gap between academia and large pharmaceutical companies, the biotech firms have been effective instruments of technology transfer.
科研通智能强力驱动
Strongly Powered by AbleSci AI